Compare · CRL vs LUNA
CRL vs LUNA
Side-by-side comparison of Charles River Laboratories International Inc. (CRL) and Luna Innovations Incorporated (LUNA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CRL and LUNA operate in Biotechnology: Commercial Physical & Biological Resarch (Health Care), so they compete in similar markets.
- CRL is the larger of the two at $8.77B, about 40.5x LUNA ($216.7M).
- Over the past year, CRL is up 34.9% and LUNA is up 0.0% - CRL leads by 34.9 points.
- CRL has hit the wire 23 times in the past 4 weeks while LUNA has been quiet.
- CRL has more recent analyst coverage (25 ratings vs 4 for LUNA).
- Company
- Charles River Laboratories International Inc.
- Luna Innovations Incorporated
- Price
- $182.14+0.80%
- $0.88-57.07%
- Market cap
- $8.77B
- $216.7M
- 1M return
- +9.13%
- +0.00%
- 1Y return
- +34.90%
- +0.00%
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- Biotechnology: Commercial Physical & Biological Resarch
- Exchange
- NYSE
- NASDAQ
- IPO
- 2000
- 2006
- News (4w)
- 23
- 0
- Recent ratings
- 25
- 4
Charles River Laboratories International Inc.
Charles River Laboratories International, Inc., an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The RMS segment produces and sells research model strains and purpose-bred rats and mice for use by researchers. It also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets and chemical compounds through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. It also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company was founded in 1947 and is based in Wilmington, Massachusetts.
Luna Innovations Incorporated
Luna Innovations Incorporated develops, manufactures, and markets fiber optic test, measurement, and control products worldwide. It operates through two segments, Lightwave and Luna Labs. The Lightwave segment offers test and measurement products, which include optical vector analyzer, optical backscatter reflectometers, and the Phoenix family of tunable lasers; and Hyperion sensing solution that enable full-spectrum data acquisition and flexible peak detect algorithms of fiber-bragg grating (FBG), long period FBGs and fabry-perot sensors with low-latency access to data for closed loop feedback applications. This segment also provides polarization control products, including components, modules, and instruments to measure, manage, and control polarization and group delay in fiber optic networks; tunable lasers; Terametrix terahertz gauging and imaging products that provides precise single and multi-layer thickness, density, basis weight, and caliper thickness measurements; ODiSI sensing solution, which provides distributed strain and temperature measurements; and Hyperion sensing products that targets fiber optic sensing applications. The Luna Labs segment provides applied research for customers principally in the areas of sensing and materials, such as coatings, adhesives, composites, and bio-engineered materials. The company sells its products to telecommunications companies, defense agencies, government system integrators, researchers, original equipment manufacturers, distributors, testing labs, and strategic partners directly, as well as through manufacturer representative organizations, partner and distribution channels, technical sales engineers, value added resellers, and independent sales representatives. Luna Innovations Incorporated was incorporated in 1990 and is headquartered in Roanoke, Virginia.
Latest CRL
- Charles River Laboratories to Present at William Blair and Jefferies Conferences
- Charles River upgraded by CLSA with a new price target
- EVP & Chief People Officer Creamer Victoria L covered exercise/tax liability with 346 shares, decreasing direct ownership by 1% to 25,726 units (SEC Form 4)
- CEVP, Disc & Safety Assessment Parisotto Shannon M gifted 7,169 shares, received a gift of 7,169 shares and covered exercise/tax liability with 273 shares, decreasing direct ownership by 49% to 7,742 units (SEC Form 4)
- EVP, Chief Information Officer Mintz Mark covered exercise/tax liability with 111 shares, decreasing direct ownership by 1% to 7,381 units (SEC Form 4)
- Chief Executive Officer Girshick Birgit covered exercise/tax liability with 618 shares, decreasing direct ownership by 2% to 31,020 units (SEC Form 4)
- SVP, Finance and CAO Knell Michael Gunnar covered exercise/tax liability with 87 shares, decreasing direct ownership by 0.60% to 14,515 units (SEC Form 4)
- EVP, Corp Strategy & Develop Laplume Joseph W covered exercise/tax liability with 428 shares, decreasing direct ownership by 2% to 27,020 units (SEC Form 4)
- Director Andrews Nancy C gifted 3,964 shares and received a gift of 3,964 shares, decreasing direct ownership by 73% to 1,438 units (SEC Form 4)
- Charles River Laboratories and MEDIPOST Sign Non-Exclusive MOU to Advance GMP Testing Solutions
Latest LUNA
- Luna Innovations Incorporated - Notice of Pendency and Proposed Settlement of Stockholder Derivative Action
- Luna Innovations Reports Q3 2025 Results Including Continued Bookings Growth and Margin Expansion
- Luna Announces Strong Start to 2025 with Substantial Bookings Growth
- Luna Innovations Announces Baker Tilly as New Independent Auditor
- Luna Innovations Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits
- Luna Announces Updates on Operating Metrics and Intent to Deregister Stock
- SEC Form SCHEDULE 13G filed by Luna Innovations Incorporated
- Luna Innovations Incorporated filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Financial Statements and Exhibits
- Luna Innovations Stock to Be Suspended from Nasdaq Listing
- Director Spiegel Gary converted options into 10,672 shares, increasing direct ownership by 15% to 81,625 units (SEC Form 4)